Cannabis Report
Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

Add PRPO Price Alert      Hide Sticky   Hide Intro
Moderator: beambe
Search This Board: 
Last Post: 7/13/2018 11:38:56 PM - Followers: 76 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1897   PRPO 8K from 7/6 aries4747 07/13/18 11:38:56 PM
#1896   I believe also there is tremendous upside here laser777 07/11/18 07:25:00 AM
#1895   Continuing to buy this puppy at these prices PennyStockTrader2 07/10/18 09:37:44 PM
#1894   Today in my opinion will be the last actsnow 06/19/18 12:46:57 PM
#1893   Some entity wants your shares, don't get tricked! actsnow 06/19/18 09:45:51 AM
#1892   Billion dollar industry, this is AWESOME news! actsnow 06/19/18 09:26:45 AM
#1891   Precipio Inc. Announces Adjournment of Annual Meeting of Shareholders aries4747 06/17/18 01:21:44 PM
#1890   Most encouraging aspect of shareholder meeting was that aries4747 06/15/18 10:01:10 AM
#1889   Meeting started at 9;30am eastern. Must be going well. mgland 06/15/18 09:49:16 AM
#1888   Looking good. aries4747 06/15/18 09:47:45 AM
#1887   If it was after the close it would mgland 06/14/18 07:14:42 PM
#1886   Having this on a FRIDAY should scare you. SidVicious 06/14/18 07:02:26 PM
#1885   I'm betting we get something positive. The proxy mgland 06/14/18 05:18:58 PM
#1884   Is it something that we should be worried 1234554321 RBM 06/14/18 05:13:18 PM
#1883   the Company's upcoming Annual General Meeting which will mgland 06/14/18 04:10:26 PM
#1882   couple of warm ups but I’m ready for my name is 06/14/18 10:05:22 AM
#1881   Nice early volume. aries4747 06/13/18 10:02:23 AM
#1880   Lets do this again. mgland 06/12/18 10:57:38 AM
#1879   chart is looking tight. not much room to my name is 06/07/18 10:22:02 AM
#1878   Well, I definitely expected a better response with mpp1 06/06/18 02:25:38 PM
#1877   Precipio Strengthens Patent Portfolio with Expanded Kit Claims actsnow 06/06/18 08:12:39 AM
#1876   Easy 10 bagger here IMHO! actsnow 06/06/18 08:10:19 AM
#1875   New Patent out, to da moon! actsnow 06/06/18 08:03:31 AM
#1874   ?? my name is 05/30/18 08:35:22 PM
#1873   Slow & steady people are loading long term stock1ace1 05/25/18 12:59:57 PM
#1872   as of now i say it hangs out my name is 05/25/18 10:16:59 AM
#1871   I see the loser is back with his laser777 05/24/18 05:52:28 PM
#1870   * * $PRPO Video Chart 05-24-18 * * ClayTrader 05/24/18 04:54:36 PM
#1869   lol relax smoke some herbs...and watch it climb MRJFK67 05/24/18 03:01:54 PM
#1868   relax buddy and look in a mirror my name is 05/24/18 01:48:22 PM
#1867   Why sell under $5? volumes say higher in time.... vlispxpert 05/24/18 01:46:43 PM
#1866   anyone buying at these levels and wont sell my name is 05/24/18 01:45:01 PM
#1865   sheesh, you're right...then I'm upping my target to $50+...muhahahahah vlispxpert 05/24/18 01:44:05 PM
#1864   You can clearly see with 22+ mill volume vlispxpert 05/24/18 01:37:20 PM
#1863   THis stock was once 25$ ! stock1ace1 05/24/18 01:31:21 PM
#1862   This is big boys controlled stock small vlispxpert 05/24/18 01:27:26 PM
#1861   Did u read this vlispxpert from news today? stock1ace1 05/24/18 01:03:53 PM
#1860   It's over 50 day...even the 1.75 pop snuck vlispxpert 05/24/18 12:20:22 PM
#1859   Why would anyone sell this? lmaoooo vlispxpert 05/24/18 12:19:12 PM
#1858   they're going start chasing pretty soon.. MRJFK67 05/24/18 11:19:50 AM
#1857   Wont hold it down much longer stock1ace1 05/24/18 11:08:05 AM
#1856   Shorts attacking every run looks like stock1ace1 05/24/18 11:07:53 AM
#1855   good NEWS beambe 05/24/18 10:29:42 AM
#1854   Beambe ~> from news $10 million annual Europe stock1ace1 05/24/18 08:50:45 AM
#1853   Prpo news thus am ! stock1ace1 05/24/18 08:40:05 AM
#1852   holly cow man. chill. my name is 05/22/18 06:21:52 PM
#1851   Congrats to everyone in today holding their shares!!! 867moneytime 05/22/18 05:02:53 PM
#1850   $PRPO is steadily rising up after hours. ;). 867moneytime 05/22/18 05:02:01 PM
#1849   HUUUGE follow up NEWS coming. ;). Don’t miss 867moneytime 05/22/18 04:15:19 PM
#1848   * * $PRPO Video Chart 05-22-18 * * ClayTrader 05/22/18 04:14:10 PM